ACTG 5359 stopped early: Could long-acting ART be a breakthrough for patients with #Adherence issues? Durable suppression—even in the never-suppressed—signals major progress. bit.ly/4gXrnoZ #HIV #Antiretroviral #CROI2025 Aadia Rana MD UC San Francisco Joseph Cherabie MD, MSc 🏳️‍🌈 (He/They)

Rates of STIs are climbing—& congenital #Syphilis has doubled since 2019, especially among cisgender women. Learn more on how to test and treat patients: bit.ly/42ZexBC #Doxycycline #Chlamydia #Gonorrhea #IDTwitter #InfectiousDisease #STI

“More cuts mean more illness.” With zero state #HIVPrevention funding in MS, AL, and LA, federal clawbacks are devastating outreach—especially for patients facing housing and care barriers. bit.ly/42TTnpM #HIVPrevention #HousingShortage #RuralHealth

ATHENA data challenge the universality of early #HIVTreatment. “Controllers off ART had fewer non-AIDS events—including fractures & #CKD—than standard ART users,” says Laura Waters. bit.ly/4cRFMT2 #HIVResearch #Antiretrovirals

Women with #HIV in mid-life face unique complexities in #ART management—requiring integrated care for co-morbidities like #HepC & tailored #ReproductiveHealth strategies. Read our latest report.bit.ly/3PPHTfK #Obstetrics #OBGYN #WomensHealth nychealthy

“We will only get to the end of #HIV if communities remain the beating heart & the strategic brains of the response. Community action is what gives science its soul.” – Rosemary Mburu, WACI Health bit.ly/40tdNnQ #IAS2025 #HIVScience #GlobalHealth #HIVPrevention

#IAS2025: “Integration is not a solution … without decriminalization, accountability, funding … it will be a death sentence for us.” -Yvette Raphael, APHA, activists reminded us: science must include & protect the Community. bit.ly/40tdNnQ #HIV #HIVPrevention

Should people with HIV interrupt treatment for cure research? ATI trials pose long-term risks, but most lack follow-up beyond 10 years. bit.ly/3PV5rzC #HIVResearch #Bioethics #AntiretroviralTherapy #HIVCure #HIV Amaya Perez-Brumer The Lancet HIV UC San Diego

Recent U.S. data show a strong inverse, dose-response link between #PrEP coverage & #HIV diagnoses—states with highest uptake see the steepest declines. bit.ly/43PLMYi The Lancet HIV #HIV #HIVPrevention #PublicHealth Emory Public Health Wellness and Equity Alliance

Over 30 years, ICU mortality for patients with advanced #HIV dropped from 36% to 14%—a striking gain. But today’s ICU patients are older, sicker & more complex. Late diagnosis still drives critical illness. bit.ly/4lPjPYF #HIVCare #CriticalCare #IDTwitter

Women with #HIV in mid-life face unique complexities in #ART management—requiring integrated care for co-morbidities like #HepC & tailored reproductive health strategies. bit.ly/3PPHTfK #Obstetrics #OBGYN nychealthy

Just 11% of 13K+ people with #HIV at a major US clinic had presumptive #Measles immunity. Amid rising cases, Dr. Benjamin Young urges HIV providers to stay alert to added risks. bit.ly/3HAAobH #MMRVaccine Parkland Health Clinical Infectious Diseases Wellness and Equity Alliance

New data from HPTN 083: CAB-LA modestly improves #BMD, while FTC/TDF causes small but measurable losses. Bone health should factor into #PrEP decisions—especially for youth, older adults, & those with fracture risk. bit.ly/4nMV809 #HIV #BoneMineralDensity Clinical Infectious Diseases

“The cancellation of the entire Adolescent Trials Network is particularly shocking… Adolescents are our future.” — Chris Beyrer urges Congress to restore #HIV research funding. bit.ly/4ipPhdD #HIVResearch #AdolescentHealth

Study LNP X: Efficient #mRNA delivery to resting T-cells to reverse # HIV latency LNP X enables potent, non-toxic mRNA transfection of resting CD4+ T-cells—advancing latency reversal strategies without activation. bit.ly/4eevj53 #HIVResearch Doherty Institute

“Our study says categorically that it’s not the medicines people have been taking for #HIV that are the culprit” for #WeightGain in people with HIV, according to Richard A. Elion, MD. More here: bit.ly/3IJvHwB

#IAS2025 Update: MK‑8527 shows promise as a once‑monthly oral #PrEP—safe, well‑tolerated, steady pharmacokinetics & no CD4/lymphocyte declines. Next up: large-scale efficacy trials across Africa & other high-risk regions. #HIVPrevention bit.ly/3GZOO52 Ken Mayer

FDA recently approved lenacapavir for #PrEP—marking the first new prevention option in nearly 4 years. Laura Waters unpacks what this means for clinics & patient care with Myles Helfand. bit.ly/4lYFcq5 #HIVPrevention #HIVCare #HIV

Did you see CDC's revised HIV #nPEP guidelines that stress urgency? Recommendation is to initiate ART within 72h of exposure, even before labs return. #Biktarvy now a preferred 1-pill daily option. bit.ly/4jNPQ1b #HIV #IDTwitter Joseph Cherabie MD, MSc 🏳️‍🌈 (He/They)

ACTG 5359 stopped early: Could long-acting ART be a breakthrough for patients with #Adherence issues? Durable suppression—even in the never-suppressed—signals major progress. bit.ly/4gXrnoZ #HIV #Antiretroviral #CROI2025 Aadia Rana MD UC San Francisco Joseph Cherabie MD, MSc 🏳️‍🌈 (He/They)